Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer
Webinar/Online
Tuesday, December 3, 2024 at 7:00pm CT - 8:00pm CT
Add this event to your calendar
Info
Topic
Lung Cancer
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
Accreditation Council for Continuing Medical Education.
Additional Information
Learning objectives:
- Appraise the biologic and clinical relevance of HER3 in advanced NSCLC and EGFR- resistant NSCLC.
- Summarize the clinical trial data and design of ongoing trials with HER3-targeted antibodies in the management of NSCLC.
- Evaluate the relevance of members of the multidisciplinary team in adverse event monitoring and management with HER3-directed therapies
Speakers
Dr. Shayma Kazmi is a Medical Oncologist and Hematologist at Penn Abramson Cancer Center, University of Pennsylvania. She also serves as an Assistant Professor of Medicine at Rowan School of Medicine in Stratford, NJ.
Event Agenda
Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer
Event Agenda
Tuesday, December 3, 2024 at 7:00pm CT - 8:00pm CT
All times listed in
Central Time (US & Canada).
Download event agenda (PDF)
Tuesday, December 3, 2024
-
7:00pm - 8:00pm
Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer
Shayma Kazmi, MD
1.0 CE CreditLearning Objectives:
- Appraise the biologic and clinical relevance of HER3 in advanced NSCLC and EGFR- resistant NSCLC.
- Summarize the clinical trial data and design of ongoing trials with HER3-targeted antibodies in the management of NSCLC.
- Evaluate the relevance of members of the multidisciplinary team in adverse event monitoring and management with HER3-directed therapies
Register For This Event
This event will be held via zoom. Once you complete the registration online, a zoom invitation will be e-mailed to you.